Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human umbilical cord mesenchymal stem cells (hUC-MSCs) are a type of multipotent stem cell derived from umbilical cord tissue, currently being investigated for the treatment of moderate to severe diabetic peripheral neuropathy (DPN). Administered via intramuscular injection into the medial and lateral muscle groups of the lower legs, these cells are thought to exert therapeutic effects through paracrine signaling. They secrete a variety of neurotrophic factors, such as nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), as well as angiogenic factors like vascular endothelial growth factor (VEGF). These secretions help to promote the repair of damaged peripheral nerves, improve local microcirculation, and modulate inflammatory responses. The specific protocol under investigation by Min Long, known as the RELEASE-DPN trial, evaluates a three-dose regimen (Day 0, 7, and 28) as an adjunct to conventional glycemic and pain management therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human umbilical cord mesenchymal stem cells (Human Life CORD).